Susquehanna International Group
CTKB icon

Susquehanna International Group’s Cytek Biosciences CTKB Stock Holding History

Susquehanna International Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-31,200
Closed -$209K – 12182
2024
Q1 		$209K Buy
31,200
+14,500
+87% +$115K ﹤0.01% 10508
2023
Q4 		$152K Buy
+16,700
New +$105K ﹤0.01% 10965

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's CTKB Position: Q1 2026 in Review

Susquehanna International Group increased its Cytek Biosciences (CTKB) stake by 16% in Q1 2026, buying an estimated $37.3K and bringing the position to 56,010 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #11306.

Susquehanna International Group first reported a position in CTKB in Q1 2022 and has held it in 14 quarters since. The position peaked at $2.82M in Q1 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Susquehanna International Group held 56,010 shares of Cytek Biosciences worth $245K as of Q1 2026.
  • Susquehanna International Group bought 7,907 Cytek Biosciences shares in Q1 2026, an estimated $37.3K.
  • Cytek Biosciences made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11306 holding.
  • Susquehanna International Group first reported a position in Cytek Biosciences in Q1 2022 and has held it in 14 quarters since.
  • Susquehanna International Group's Cytek Biosciences position peaked at $2.82M in Q1 2023.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.